Allergan plc () announced earlier that Robert Hugin has been appointed to its board, effective immediately. Hugin was formerly the CEO and Chairman of Celgene (CELG). In addition, the Allergan board announced its intention to recommend for a pending shareholder proposal, which will also appear in its 2019 proxy statement, requiring an Independent Board Chair to be phased in during the next leadership transition. “Today’s announcements reflect our Board’s ongoing commitment to active board refreshment and governance best practices, as well as continuous engagement with our shareholders,” said Chris Coughlin, Lead Independent Director of Allergan’s Board. “These actions enhance our Board leadership and governance policies, while preserving existing leadership arrangements, achieving a balance that we believe our shareholders will embrace.” Shares of are down 64c to $138.40 in early trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.